Alan H Bryce
@AlanBryce9
Followers
1K
Following
425
Statuses
688
Medical oncologist and cancer researcher specializing in Prostate Cancer. Chief Clinical Officer, City of Hope Arizona, Professor of Molecular Medicine,Tgen
Phoenix, AZ
Joined July 2019
RT @montypal: Stellar presentation from @neerajaiims @huntsmancancer at @ASCO #GU25. Impressive to see the benefit across subsets in #TALAP…
0
14
0
RT @montypal: Beautiful synthesis of complex datasets at @ASCO #GU25 from @TDorffOnc, leader of our GU team at @cityofhope! The “buckets” s…
0
11
0
RT @TheCancerLetter: .@walterstadler5 appointed chief clinical officer at City of Hope Cancer Center Chicago (@cityofhope)
0
3
0
RT @EAntonarakis: The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Differ…
0
16
0
RT @apolo_andrea: 📣 Last call! Deadline extended to 12/15/24 Calling all #GU junior faculty & fellows! Apply today for the 2025 GU Ear…
0
10
0
RT @quimmateo: Our review on the current state of PARPi development for #prostatecancer is now out in @EurUrolOncol - led by @FrancescaZacc…
0
19
0
An important PSA from Dr Apolo for early career GU faculty. This early thought leaders conference is intended to provide guidance for career development in GU Oncology
Calling GU junior faculty & fellows! 📣 Apply for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-3/8, led by me & @zklaassen_md. Secure your spot for 2 days of professional development & networking: @OncoAlert @SUO_YUO #SUO24
1
4
11
RT @apolo_andrea: Calling GU junior faculty & fellows! 📣 Apply for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-…
0
28
0
@Soum_Roy_RadOnc @ConquerCancerFd @ASCO @DrSpratticus @PCF_Science @PCFnews @RushRadOnc Congratulations @Soum_Roy_RadOnc
1
0
1
RT @PBarataMD: Hot of the press: our recent collaboration showing blood-based TMB not good predictive to IO in “cold tumors” breast and pro…
0
15
0
Very happy to share the manuscript from the 2024 United States Prostate Cancer Consensus Conference. Our goal with this is to address the many common clinical conundrums that occur daily in prostate cancer clinics but fall outside the areas covered by level 1 evidence. The US represents a unique regulatory environment with a breadth of options for clinicians that is not present anywhere else, thus the choices faced by our practitioners are unique and we address many of them here. Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 - Bryce - Cancer - Wiley Online Library
4
28
74
Great news. This potentially adds a new class of targeted therapy for mHSPC. PTEN deficiency is present in around 40% of cases. Looking forward to seeing the full data.
💫🌟📢 Exciting news in prostate cancer! Key highlights from the CAPItello-281 trial on Truqap (#capivasertib)🌟💫 @OncoAlert @AstraZeneca 🔹 First AKT inhibitor combination to show benefits in PTEN-deficient #mHSPC. 🔹 Significant improvement in rPFS vs. abiraterone + ADT with placebo. 🔹 Early trend in OS, with further data to come. 🔹 PTEN-deficient de novo mHSPC: an aggressive subtype with poor prognosis. 🔹 Safety profile consistent with known medication profiles. 🌟 A step forward for patients with unmet needs. #CAPItello281 #ProstateCancer #AKTInhibitor #Oncology
0
2
10
@DrRanaMcKay @CaPsurvivorship @EAntonarakis @RenuEapen @zklaassen_md Another trendsetter moment from You @DrRanaMcKay. Tomorrow everyone in Vienna will be wearing those.
0
0
2
And this is another reason to vote for @DrRanaMcKay for the ASCO nominating committee!
What a fantastic experience! So critical to model healthy habits….diet, exercise, positive attitude….keys to success. I challenge national and international meeting planners to integrate into programming! @ASCO @myESMO @ASTRO_org @UCSDHealth @UroOnc @sitcancer @AACR
0
0
9
Dr McKay, “if I wasn’t an oncologist I’d be a personal trainer”. Dr McKay is ever a trendsetter. I won’t be surprised if we see others following her lead here.
0
0
7
Great opportunity for young GU faculty to network and learn about career advancement strategies.
Taking applications for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-3/8, led by @apolo_andrea and myself! Secure your spot for two days of professional development and networking here: @urotoday @PCFnews @PhillipKooMD
0
2
5
Fantastic work by @SyedArsalanN. Program directors please take note- He is a rising talent who is currently applying no for IM residencies.
@MayoCancerCare post doc @SyedArsalanN leading the way with a first author oral presentation and two first author poster presentations #VAHC2024 @AMIAinformatics. What a talent! #Superstar @AlanBryce9
1
3
12
Important research demonstrating the Immunogenic Cell Death mechanism of PT-112. The phase 2 dose finding study in mCRPC has completed accrual and we eagerly await the results.
Excited to publish findings on PT-112's mechanism in prostate cancer cells, related to Phase 2 clinical development of PT-112 in patients with mCRPC. Thank you to my co-authors for their support and collaboration on this work! #oncologyresearch
0
3
3